Am I mistaken in my understanding that the P2 M/M "Other Outcome Measures" does NOT include viral load? I would have thought that would have been an important data point to present to the FDA. Maybe I'm just not reading this correctly.

Link: https://clinicaltrials.gov/ct2/show/NCT04343651

Quote:

---

Other Outcome Measures:
Change in size of lesion area by chest radiograph or CT [ Time Frame: Day 14 ]
Change from baseline in serum cytokine and chemokine levels [ Time Frame: Days 3, 7, and 14 ]
Change from baseline in CCR5 receptor occupancy levels for Tregs and macrophages [ Time Frame: Days 3, 7, and 14 ]
Change from baseline in CD3+, CD4+ and CD8+ T cell count [ Time Frame: Days 3, 7, and 14 ]

---